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Emmakate Buchanan, Ouzmah ShafiqA move towards bloodless hepatic
resection
Resection of liver tumours with minimal blood loss
may now be possible using the ‘‘Habib 4x resection
device,’’ pioneered by Professor Nagy Habib of
Imperial College, United Kingdom. The hand-held
device transmits radiofrequency waves via 4 electro-
des into the tissue. Subsequent dehydration creates
a seal, thus a scalpel alone is sufficient for resection,
making glue, ties, sutures and staples redundant. In
tests, blood loss was diminished from 4.5 l to approx-
imately 50 ml with a similarly impressive reduction in
hospital intensive care stay. Created by EMcision, it
has been used on over 100 patients in the USA, with
zero morbidity and mortality and no recurrence
upon follow-up ranging from 2 to 20 months. The de-
vice has now been licensed for use in Europe, Profes-
sor Habib told the IJS: ‘‘This is an exciting milestone
given that the liver is the second commonest site of
cancer in the body, there is much potential of radio-
frequency technologies in surgery.’’
Int J Colorectal Dis 2005;20:521e8.
Figure 1 A model of how the Habib 4x would work.
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doi:10.1016/j.ijsu.2005.10.009Introducing the Southampton
Remedi-Hand
An artificial hand has been developed by Dr Paul
Chappell and the team at Southampton University,
United Kingdom. Chappell’s design aims to mimic
a real hand enabling fine movement, opposi-
tion and grip. Dr Chappell told the IJS: ‘‘The
Southampton-Remedi Hand can adopt a variety of
grip patterns. It can clutch objects such as a ball,
or the thumb can move out to one side and grip
objects with the index finger in the way you do
when opening a lock with a key. The fingers can
wrap around an object in a power grip e like the
one you use when holding a hammer’’.
Figure 2 The Habib 4x in action.
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Remedi Hand to ‘sense’ its surroundings. Dr
Chappell commented: ‘‘Sensors on the fingertips
will be able to feel the object they are gripping
and then transfer this information to the mechan-
ics of the hand through suitable electronic cir-
cuits to adjust its grip. If the hand is holding an
egg, for instance, we want it to realise that
a delicate grip is required. If, conversely, the
hand is gripping a door handle it may require
a firmer grip. The vision is to have a hand that
senses these subtle nuances independently’’. Dr
Chappell hopes future hands will be able to
combine information from a number of different
sensors such as force, object-slip, finger position
and temperature to adjust the posture of the
hand and grip strength.
Antibiotic-coated implants e a
breakthrough
Antibiotics attached to Titanium surfaces may help
to prevent the complication of infection and sub-
sequent implant failure following Orthopaedic
surgery. The discovery of a permanent chemical
bond between Vancomycin and Titanium by re-
searchers at Jefferson Medical College, USA, would
also provide protection against infection which
may develop later from a different primary focus
such as a dental procedure. The principle is
applicable to a variety of implantations, from
pacemakers to catheters. The chemical bond is
of the same duration as the implant and actively
reduces re-infection once bound.
Clin Orthop Relat Res 2004;(429):33e8.
Figure 3 The Southampton Remedi-Hand in action.Level I trauma centres increase chance
of survival
US trauma patients are transferred by paramed-
ics to the nearest trauma centre independent of
their injuries. Dr Demetrios Demetriades and
researchers at the University of Southern Cali-
fornia found that patients admitted to level I
trauma centres were 20% less likely to die. In
addition, 20% of trauma patients discharged from
level I facilities were severely disabled, com-
pared with 34% from level II facilities. Their
information was drawn from records stored at
the National Trauma Data Bank. A level I facility
is a regional academic trauma centre. It must
include a 24-h operating suite, a fully staffed
intensive care service, in-house CT scan techni-
cians, MRI, acute haemodialysis and a comprehen-
sive surgical residency programme. Surgical
specialties on site include general surgery, car-
diac surgery, microvascular and replantation
surgery. Dr Demetriades hopes that the findings
could influence how trauma centres are organ-
ised and patients are triaged.
Annals of Surgery 2005;242:512e519.
Figure 4 Antibiotic-coated implants.
News 249Cervical cancer vaccination e initial trial
results hold promise
Initial results from Future II, the trial of Merck’s
quadrivalent recombinant vaccine Gardasil, have
proved ‘‘100% efficacious’’. Gardasil, is genetically
engineered to block infection with HPV 16 and 18,
two sexually transmitted viruses responsible for
circa 70% of cervical cancers. The vaccine also
appears to act against HPV strains 6 and 11 causing
genital warts. Future II is a prospective, rando-
mised, double-blind, placebo-controlled study
with two vaccination groups. Women aged 16e26
years were randomised to receive a three-dose
regimen of either Gardasil or placebo at day 1,
month 2 and month 6. A total of 12,167 women
were enrolled from 90 study centres.
A step forward for ovarian
transplantation
Scientists at the Institute of Animal Science in
Israel, have successfully thawed and transplanted
whole sheep ovaries. Dr Amir Arav and his team
removed one whole ovary together with its blood
vessels from eight sheep. Over the next three to
fourteen days each ovary was thawed and trans-
planted back into the sheep from which it was
originally removed. It is not known whether this
technique could be transferred to humans. The
team hope their experiment will shed light on the
problem of how to preserve fertility in women at
risk of premature ovarian failure through chemo-
therapy regimens.
Human lung epithelium grown from
stem cells
Human embryonic stem cells have been converted
into mature small airway epithelium by Dame Julia
Polak and her team at Imperial College, United
Kingdom. These cells were grown in a specialised
system to foster gaseous exchange conversion.
This will be further tested on other sources of
stem cells such as umbilical cord blood and bone
marrow. The epithelium would be suitable to
repair the lung lining in conditions such as Acute
Respiratory Distress Syndrome (ARDS), a major
cause of morbidity in intensive care patients.
Dame Julia Polak told the IJS: ‘‘This excitingdevelopment is the first huge step towards human
lung transplantation’’.
Tissue Eng 2005;11:1177e87.
Gold nanoparticles e a new paradigm for
cancer therapy?
Researchers in the United States have found
a novel way to detect and destroy cancer utilising
the fact that many cancers express epidermal
growth factor receptor (EGFR) protein on their
surface. They found that conjugating gold nano-
particles to an antibody for the EGFR, resulted in
nanoparticles attaching themselves to the rogue
protein. Recently they have shown that heating
the same gold nanoparticles destroys malignant
cells to which they are attached. Researchers
incubated two oral squamous carcinoma cell lines
and one benign epithelial cell line with antibody
conjugated gold nanoparticles. The cell lines were
then exposed to a continuous visible argon laser;
malignant cells required less than half the laser
energy to be destroyed compared with benign
cells. Assistant Professor Ivan El-Sayed hopes gold
nanoparticles will be used to map and destroy
different types of cancer.
Cancer Letters. In press. Available on Science-
Direct (published 28 September 2005).
Myocardial regeneration using mouse
stem cells
Murine embryonic stem cells have been used to
repair damaged sheep hearts by Michel Puceat at
the French National Centre for Scientific Research.
Replacement of damaged tissue was identified
using specific stem cell markers within the im-
proved heart. Increased blood flow to infarcted
regions of myocardium in rodents, has already
proved possible with embryonic stem cells. A 15%
increase in the efficiency of myocardial contrac-
tion was achieved upon injecting 30 million stem
cells into 9 previously infarcted sheep hearts.
Human trials to date have used bone marrow
stem cells, which produce a similar but smaller
effect. Further investigations with baboon myo-
cardium and human embryonic stem cells are
underway.
Lancet 2005;366:1005e12.
